Inke S.A., a wholly-owned subsidiary of Neuraxpharm, is focused since 1980 in the development and manufacture of the highest quality Active Pharmaceutical Ingredients (APIs) with complex synthesis processes, mainly for use in Respiratory and Central Nervous Systems (CNS) therapies. Based in Barcelona (Spain) and counting more than twenty years’ experience in micronization, Inke is in continuous international expansion since 1998, delivering APIs all over the world, including US, Europe and Japan. Inke develops, patents and implements its own synthesis routes for the manufacture of active substances. Given the specific requirements for these products, this strategic commitment has involved an increase in the level of technical and regulatory collaboration with our customers. Inke has been successfully inspected by every major global authority for a wide array of products (last US-FDA inspection was in April 2019). For the last two decades, the company has made strong strides to become a prestige provider of respiratory APIs for inhalation. To learn more about our expertise in inhalation therapies, please get in touch at email [email protected]